Javier
Rodríguez Rodríguez
Consultor Médico
Eva
Bandres Elizalde
Forscherin bis um 2004
Publikationen, an denen er mitarbeitet Eva Bandres Elizalde (11)
2013
-
Valoración de marcadores pronósticos de respuesta a bevacizumab en pacientes con cáncer colorrectal avanzado y su utilidad para la individualización del tratamiento
Anales del sistema sanitario de Navarra, Vol. 36, Núm. 1, pp. 174-177
2012
-
Fc gamma receptor polymorphisms as predictive markers of Cetuximab efficacy in epidermal growth factor receptor downstream-mutated metastatic colorectal cancer
European Journal of Cancer, Vol. 48, Núm. 12, pp. 1774-1780
-
Identification of colorectal cancer metastasis markers by an angiogenesis-related cytokine-antibody array
World Journal of Gastroenterology, Vol. 18, Núm. 7, pp. 637-645
-
Identification of predictive circulating biomarkers of bevacizumab- containing regimen efficacy in pre-treated metastatic colorectal cancer patients
British Journal of Cancer, Vol. 107, Núm. 2, pp. 287-290
2011
-
Association of RRM1 -37A>C polymorphism with clinical outcome in colorectal cancer patients treated with gemcitabine-based chemotherapy
European Journal of Cancer, Vol. 47, Núm. 6, pp. 839-847
-
MicroRNA-451 is involved in the self-renewal, tumorigenicity, and chemoresistance of colorectal cancer stem cells
Stem Cells, Vol. 29, Núm. 11, pp. 1661-1671
2010
-
Dose-finding study and pharmacogenomic analysis of fixed-rate infusion of gemcitabine, irinotecan and bevacizumab in pretreated metastatic colorectal cancer patients
British Journal of Cancer, Vol. 103, Núm. 10, pp. 1529-1535
-
Oxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): A dose-finding study and pharmacogenomic analysis
British Journal of Cancer, Vol. 102, Núm. 6, pp. 987-994
-
miR-192/miR-215 influence 5-fluorouracil resistance through cell cycle-mediated mechanisms complementary to its post-transcriptional thymidilate synthase regulation
Molecular Cancer Therapeutics, Vol. 9, Núm. 8, pp. 2265-2275
2009
-
microRNA-451 regulates macrophage migration inhibitory factor production and proliferation of gastrointestinal cancer cells
Clinical Cancer Research, Vol. 15, Núm. 7, pp. 2281-2290
2007
-
Combining chemotherapy and targeted therapies in metastatic colorectal cancer
World Journal of Gastroenterology, Vol. 13, Núm. 44, pp. 5867-5876